ABT-122, a bispecific monoclonal antibody that neutralizes both TNF and IL17A, was the first of this class to be developed, initially assessed in PsA in a phase 2 trial (240 PsA patients) and in RA (16, 19, 20). This evidence concerns the gene IL17A and rheumatoid arthritis.